PIRS - FDA lifts partial hold on Pieris' early-stage study of lead drug

The FDA has lifted partial clinical hold on Phase 1 studies evaluating Pieris Pharmaceuticals' ([[PIRS]] +3.4%) lead candidate, PRS-343. As previously guided, the Company intends to move into a proof-of-concept study of PRS-343 in gastroesophageal cancer.The FDA instituted a partial clinical hold on the trials until the company conducts an additional in-use and compatibility study with various infusion materials under specific conditions aimed at confirming the suitability of the PRS-343 for administration in clinical settings.

For further details see:

FDA lifts partial hold on Pieris' early-stage study of lead drug